Cargando…

肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究

Background and objective The morbidity and mortality rates of lung cancer remain high worldwide, and lung adenocarcinoma is one of the most important tissue subtypes of lung cancer. Epidermal growth factor receptor (EGFR) mutation is an important driver gene mutation for lung adenocarcinoma. In rece...

Descripción completa

Detalles Bibliográficos
Autores principales: ZHU, Hongyu, CHEN, Peng, DONG, Guozhang, MENG, Fanchen, XIA, Zhijun, YOU, Jing, KONG, Xiangru, WU, Jintao, YUAN, Fangwei, YU, Xinyu, SUN, Qinhong, JI, Jinfu, WANG, Siwei, LIU, Tongyan, XU, Lin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Editorial board of Chinese Journal of Lung Cancer 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106792/
https://www.ncbi.nlm.nih.gov/pubmed/37035883
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.07
_version_ 1785026483810467840
author ZHU, Hongyu
CHEN, Peng
DONG, Guozhang
MENG, Fanchen
XIA, Zhijun
YOU, Jing
KONG, Xiangru
WU, Jintao
YUAN, Fangwei
YU, Xinyu
SUN, Qinhong
JI, Jinfu
WANG, Siwei
LIU, Tongyan
XU, Lin
author_facet ZHU, Hongyu
CHEN, Peng
DONG, Guozhang
MENG, Fanchen
XIA, Zhijun
YOU, Jing
KONG, Xiangru
WU, Jintao
YUAN, Fangwei
YU, Xinyu
SUN, Qinhong
JI, Jinfu
WANG, Siwei
LIU, Tongyan
XU, Lin
author_sort ZHU, Hongyu
collection PubMed
description Background and objective The morbidity and mortality rates of lung cancer remain high worldwide, and lung adenocarcinoma is one of the most important tissue subtypes of lung cancer. Epidermal growth factor receptor (EGFR) mutation is an important driver gene mutation for lung adenocarcinoma. In recent years, immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, have achieved remarkable efficacy in some lung cancer patients. Patients with EGFR mutations enjoyed limited benefits from immunotherapy according to recent studies. This study aimed to explore the relationship between EGFR mutation status and the spatial distribution as well as infiltration number of various immune cells in patients with EGFR mutant lung adenocarcinoma. Methods This study included 62 lung adenocarcinoma patients who underwent surgery. Through multi-point sampling of surgically removed tumor tissues in different areas, 223 tumor tissue samples were finally obtained. We aquired EGFR mutations status including variant allele frequency (VAF) and mutation subtype in each tumor tissue by genetic test. Afterwards, hematoxylin-eosin (HE) staining, immunohistochemical staining and multiplex fluorescence immunohistochemistry staining have been performed, therefore the infiltration of various immune cells and the distribution of tertiary lymphoid structure (TLS) in tumor tissues were obtained by calculating the immunohistochemical score. Results Compared with EGFR wild-type patients, patients with EGFR-mutant lung adenocarcinoma had more infiltration of CD68(+) macrophages and major histocompatibility complex (MHC) class II antigen-presenting cells and higher spatial distribution heterogeneity of MHC class II antigen presenting cells in tumor tissues, while CD56(+) natural killer cells and CD8(+) T cells had lower infiltration. Tumor tissues with higher EGFR VAF were associated with lower cell infiltration such as CD3(+) T cells, CD20(+) B cells, CD56(+) natural killer cells, CD68(+) macrophages, CD8(+) T cells, and only CD3(+) T cells showed a lower spatial distribution heterogeneity. For the two common subtypes of EGFR mutations in Chinese population, tumor tissues with EGFR exon 19 deletion mutations have lower immune cell infiltration but higher spatial distribution heterogeneity of CD3(+) T cells, CD56(+) natural killer cells, CD68(+) macrophages, and CD8(+) T cells than that in EGFR exon 21 L858R mutant tumor tissues. Prognostic analysis found that patients with EGFR mutations with high degree of CD3(+) T cells, CD20(+) B cell infiltration and larger numbers of TLS formation and high spatial distribution heterogeneity of CD8(+ )T cell had longer disease-free survival. Conclusion EGFR-mutated lung adenocarcinoma had a unique "non-inflammatory" tumor microenvironment with low infiltration of immune cells, and there was also heterogeneity in the tumor microenvironment among the tumors with different mutation subtypes and mutation abundance. These differences were not only reflected in the number but also the spatial distribution of immune cell infiltration. Hence, further studies on the immune microenvironment of EGFR-mutant lung adenocarcinoma were of great significance for improving the efficacy of immunotherapy in EGFR-mutant lung adenocarcinoma patients in the future.
format Online
Article
Text
id pubmed-10106792
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Editorial board of Chinese Journal of Lung Cancer
record_format MEDLINE/PubMed
spelling pubmed-101067922023-04-18 肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究 ZHU, Hongyu CHEN, Peng DONG, Guozhang MENG, Fanchen XIA, Zhijun YOU, Jing KONG, Xiangru WU, Jintao YUAN, Fangwei YU, Xinyu SUN, Qinhong JI, Jinfu WANG, Siwei LIU, Tongyan XU, Lin Zhongguo Fei Ai Za Zhi Clinical Research Background and objective The morbidity and mortality rates of lung cancer remain high worldwide, and lung adenocarcinoma is one of the most important tissue subtypes of lung cancer. Epidermal growth factor receptor (EGFR) mutation is an important driver gene mutation for lung adenocarcinoma. In recent years, immune checkpoint inhibitors (ICIs), such as programmed cell death 1 (PD-1) and programmed cell death ligand 1 (PD-L1) inhibitors, have achieved remarkable efficacy in some lung cancer patients. Patients with EGFR mutations enjoyed limited benefits from immunotherapy according to recent studies. This study aimed to explore the relationship between EGFR mutation status and the spatial distribution as well as infiltration number of various immune cells in patients with EGFR mutant lung adenocarcinoma. Methods This study included 62 lung adenocarcinoma patients who underwent surgery. Through multi-point sampling of surgically removed tumor tissues in different areas, 223 tumor tissue samples were finally obtained. We aquired EGFR mutations status including variant allele frequency (VAF) and mutation subtype in each tumor tissue by genetic test. Afterwards, hematoxylin-eosin (HE) staining, immunohistochemical staining and multiplex fluorescence immunohistochemistry staining have been performed, therefore the infiltration of various immune cells and the distribution of tertiary lymphoid structure (TLS) in tumor tissues were obtained by calculating the immunohistochemical score. Results Compared with EGFR wild-type patients, patients with EGFR-mutant lung adenocarcinoma had more infiltration of CD68(+) macrophages and major histocompatibility complex (MHC) class II antigen-presenting cells and higher spatial distribution heterogeneity of MHC class II antigen presenting cells in tumor tissues, while CD56(+) natural killer cells and CD8(+) T cells had lower infiltration. Tumor tissues with higher EGFR VAF were associated with lower cell infiltration such as CD3(+) T cells, CD20(+) B cells, CD56(+) natural killer cells, CD68(+) macrophages, CD8(+) T cells, and only CD3(+) T cells showed a lower spatial distribution heterogeneity. For the two common subtypes of EGFR mutations in Chinese population, tumor tissues with EGFR exon 19 deletion mutations have lower immune cell infiltration but higher spatial distribution heterogeneity of CD3(+) T cells, CD56(+) natural killer cells, CD68(+) macrophages, and CD8(+) T cells than that in EGFR exon 21 L858R mutant tumor tissues. Prognostic analysis found that patients with EGFR mutations with high degree of CD3(+) T cells, CD20(+) B cell infiltration and larger numbers of TLS formation and high spatial distribution heterogeneity of CD8(+ )T cell had longer disease-free survival. Conclusion EGFR-mutated lung adenocarcinoma had a unique "non-inflammatory" tumor microenvironment with low infiltration of immune cells, and there was also heterogeneity in the tumor microenvironment among the tumors with different mutation subtypes and mutation abundance. These differences were not only reflected in the number but also the spatial distribution of immune cell infiltration. Hence, further studies on the immune microenvironment of EGFR-mutant lung adenocarcinoma were of great significance for improving the efficacy of immunotherapy in EGFR-mutant lung adenocarcinoma patients in the future. Editorial board of Chinese Journal of Lung Cancer 2023-03-20 /pmc/articles/PMC10106792/ /pubmed/37035883 http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.07 Text en https://creativecommons.org/licenses/by/3.0/This is an open access article distributed in accordance with the terms of the Creative Commons Attribution (CC BY 3.0) License. See: https://creativecommons.org/licenses/by/3.0/.
spellingShingle Clinical Research
ZHU, Hongyu
CHEN, Peng
DONG, Guozhang
MENG, Fanchen
XIA, Zhijun
YOU, Jing
KONG, Xiangru
WU, Jintao
YUAN, Fangwei
YU, Xinyu
SUN, Qinhong
JI, Jinfu
WANG, Siwei
LIU, Tongyan
XU, Lin
肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究
title 肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究
title_full 肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究
title_fullStr 肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究
title_full_unstemmed 肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究
title_short 肺腺癌中免疫微环境特征与EGFR突变状态的相关性研究
title_sort 肺腺癌中免疫微环境特征与egfr突变状态的相关性研究
topic Clinical Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10106792/
https://www.ncbi.nlm.nih.gov/pubmed/37035883
http://dx.doi.org/10.3779/j.issn.1009-3419.2023.101.07
work_keys_str_mv AT zhuhongyu fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT chenpeng fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT dongguozhang fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT mengfanchen fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT xiazhijun fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT youjing fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT kongxiangru fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT wujintao fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT yuanfangwei fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT yuxinyu fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT sunqinhong fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT jijinfu fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT wangsiwei fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT liutongyan fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū
AT xulin fèixiànáizhōngmiǎnyìwēihuánjìngtèzhēngyǔegfrtūbiànzhuàngtàidexiāngguānxìngyánjiū